KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Shares Issued (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Shares Issued for 9 consecutive years, with $657000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued rose 212.12% year-over-year to $657000.0, compared with a TTM value of $9.1 million through Dec 2025, up 164.66%, and an annual FY2025 reading of $9.1 million, up 164.66% over the prior year.
  • Shares Issued was $657000.0 for Q4 2025 at Biocryst Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Across five years, Shares Issued topped out at $5.1 million in Q1 2023 and bottomed at -$586000.0 in Q4 2024.
  • Average Shares Issued over 3 years is $1.7 million, with a median of $1.7 million recorded in 2023.
  • The sharpest move saw Shares Issued tumbled 1602.56% in 2024, then surged 1195.83% in 2025.
  • Year by year, Shares Issued stood at $39000.0 in 2023, then crashed by 1602.56% to -$586000.0 in 2024, then soared by 212.12% to $657000.0 in 2025.
  • Business Quant data shows Shares Issued for BCRX at $657000.0 in Q4 2025, $2.6 million in Q3 2025, and $3.4 million in Q2 2025.